We have released the Digital Risk Report for the U.S. Pharma, a sector-wide analysis of the digital reputation of 17 leading pharmaceutical companies with significant U.S. market presence. We ran each company through Risk Check, our AI-powered diagnostic platform, to map how controllable their digital presence really is – across media and social environments, search results, AI-generated interpretations, and consumer trust signals.
The picture that emerged is consistent across the sector: in pharma, digital reputational risk is structural, not episodic. It's shaped less by current crises and more by accumulated legal history, fragmented brand identity, and the growing influence of AI-generated content on how a brand is perceived.
Across the 17 companies, the average Composite Risk Score was 33 out of 100 – just above the boundary between our LOW and MEDIUM bands. Eleven companies landed in MEDIUM and six in LOW, with Catalent scoring highest at 42 and Amgen and Biogen lowest at 24 each. On its own, an average of 33 might suggest a healthy digital presence. We think that reading is misleading: most of these companies are not in crisis, but most carry structural vulnerabilities that could escalate quickly under a new regulatory action, a recall, or an adverse media cycle.
The most striking result concerns AI. Every company we analyzed scored MEDIUM on AI Perception – the dimension that measures the gap between how a company positions itself and how AI systems like ChatGPT, Gemini, and Perplexity describe it. At this sample size the metric doesn't yet differentiate between companies, so we report this as an early-stage, observational signal rather than a settled finding. But the pattern is clear enough to act on. AI systems draw heavily on the most authoritative, most-indexed sources – encyclopedias, news archives, government and litigation records – and for pharmaceutical brands that material disproportionately reflects regulatory actions, warning letters, pricing lawsuits, and historical controversies. Even companies with otherwise strong digital profiles inherit this framing. The legal matter may be long resolved; the digital signal persists.
This is the central takeaway of our research. As AI becomes a primary discovery surface for patients, investors, and journalists, companies face a new category of risk that traditional PR and search-optimization frameworks were never designed to address: the gap between institutional reputation and AI-mediated perception. Alongside it, we found that brand-identity fragmentation – from spinoffs, name collisions, and subsidiary confusion – is a persistent, cross-channel vulnerability that AI systems tend to amplify rather than resolve.
The picture that emerged is consistent across the sector: in pharma, digital reputational risk is structural, not episodic. It's shaped less by current crises and more by accumulated legal history, fragmented brand identity, and the growing influence of AI-generated content on how a brand is perceived.
Across the 17 companies, the average Composite Risk Score was 33 out of 100 – just above the boundary between our LOW and MEDIUM bands. Eleven companies landed in MEDIUM and six in LOW, with Catalent scoring highest at 42 and Amgen and Biogen lowest at 24 each. On its own, an average of 33 might suggest a healthy digital presence. We think that reading is misleading: most of these companies are not in crisis, but most carry structural vulnerabilities that could escalate quickly under a new regulatory action, a recall, or an adverse media cycle.
The most striking result concerns AI. Every company we analyzed scored MEDIUM on AI Perception – the dimension that measures the gap between how a company positions itself and how AI systems like ChatGPT, Gemini, and Perplexity describe it. At this sample size the metric doesn't yet differentiate between companies, so we report this as an early-stage, observational signal rather than a settled finding. But the pattern is clear enough to act on. AI systems draw heavily on the most authoritative, most-indexed sources – encyclopedias, news archives, government and litigation records – and for pharmaceutical brands that material disproportionately reflects regulatory actions, warning letters, pricing lawsuits, and historical controversies. Even companies with otherwise strong digital profiles inherit this framing. The legal matter may be long resolved; the digital signal persists.
This is the central takeaway of our research. As AI becomes a primary discovery surface for patients, investors, and journalists, companies face a new category of risk that traditional PR and search-optimization frameworks were never designed to address: the gap between institutional reputation and AI-mediated perception. Alongside it, we found that brand-identity fragmentation – from spinoffs, name collisions, and subsidiary confusion – is a persistent, cross-channel vulnerability that AI systems tend to amplify rather than resolve.
Reputation House builds digital risk protection products for companies in fintech, pharma, SaaS and beyond — with a fully remote team across three continents.
Learn more about Reputation House
Risk Check is our free diagnostic platform for digital risk. In a few minutes, it lets a company assess how stable its information environment really is – and where distortions in brand perception are most likely to form. Unlike traditional monitoring tools that surface endless streams of mentions, Risk Check works as a diagnostic system: its purpose isn't to track every mention, but to identify the structural risk points that shape how a brand is understood.
The platform evaluates four areas that define digital perception – the media and social environment, search engine results, AI interpretation, and rating and review platforms – and returns a structured report that includes an overall information-risk level, an analysis of key vulnerability zones, and an automatic comparison against relevant companies in the same sector. The process is three simple steps: data input, digital environment analysis, and a risk report. It's the same methodology, applied uniformly, that powers this study.
The platform evaluates four areas that define digital perception – the media and social environment, search engine results, AI interpretation, and rating and review platforms – and returns a structured report that includes an overall information-risk level, an analysis of key vulnerability zones, and an automatic comparison against relevant companies in the same sector. The process is three simple steps: data input, digital environment analysis, and a risk report. It's the same methodology, applied uniformly, that powers this study.
"For years, pharmaceutical companies have invested in managing search results and press coverage, and those investments still matter. But a new discovery surface has emerged. When a patient, an investor, or a journalist asks an AI system about a company today, the answer often leans on decades of indexed regulatory and litigation history rather than on where the company stands now. That gap between how a company presents itself and how AI describes it is the reputational challenge of this decade, and it's one that traditional communications was never built to address. We built Risk Check so companies can finally see that problem and act on it,"
said Kristina Shinkareva, CEO of Reputation House.
Check how AI describes your company right now Run Your Risk Check For Free Reputation House Risk Check gives pharma leadership a structured view of how the brand is perceived across search, AI answers, media, and review platforms — mapping the gap between how you present the company and how AI systems describe it.